Chromocell Therapeutics Corp.
CHRO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.78M
Close$
$-0.30
122.2% downside
Current Fair Value
122.2% downsideOvervalued by 122.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.78 Million |
|---|---|
| Enterprise Value | $27.19 Million |
| Earnings per Share | $-23.04 |
| Beta | 3.29 |
| Outstanding Shares | 3,539,464 |
Return
| Return on Equity | 4767.29% |
|---|---|
| Return on Assets | -52.10% |
| Return on Invested Capital | -28.62% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | -0.01 |
| Price to Sales | 0.11 |
| Price to Book Ratio | -1.35 |
| Enterprise Value to Revenue | 0.63 |
| Enterprise Value to EBIT | -0.9 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.71 |
| Debt to Equity | -31.05 |
Revenue Sources
No data
Last Earnings Call
Report Date
March 19, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Pelthos Therapeutics Inc.
92 employees
CEO: Scott Plesha
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medic...